From 2002 to 2013 in Montreal, Quebec, Canada, 38 Campylobacter coli isolates were more frequently erythromycin, tetracycline, and ciprofloxacin resistant than 440 Campylobacter jejuni subsp. jejuni isolates (18.4% versus 1.8%; P ‫؍‬ 0.00005), of which the 148 isolates acquired abroad were more frequently erythromycin, tetracycline, and ciprofloxacin resistant than the 292 isolates acquired locally (5.4% versus 0%; P ‫؍‬ 0.0001).
confidence limits {CL}, 0.63 [0.08 to 4.94]); 4 C. jejuni subsp. jejuni bacteremic patients also had stool cultures positive for the same Campylobacter sp. than the one isolated from their blood. Overall, 475 C. jejuni subsp. jejuni and 37 C. coli isolates were obtained from stools, with a 2.25% positive rate for these species in stools during those years. C. jejuni subsp. jejuni and C. coli were isolated more frequently from blood than reported previously (i.e., 0.15% of Campylobacter infections [2] ). The automated blood culture systems and patient immune statuses were variables that influenced the bacteremia rates (1, 2) . In the week before symptom onset, 148 C. jejuni subsp. jejuni isolates (30.9%) and 21 C. coli (55.3%) isolates were acquired abroad, outside the province of Quebec, and 331 (69.1%) C. jejuni subsp. jejuni and 17 (44.7%) C. coli isolates were acquired locally (P ϭ 0.004; RR [95% CL], 0.56 [0.41 to 0.77]), data similar to those reported previously (6) . Among these 479 C. jejuni subsp. jejuni isolates, 3 clusters were documented (7; our unpublished data) and only 1 isolate per outbreak was included in our susceptibility study, for a total of 440 C. jejuni subsp. jejuni. One C. coli isolate was involved in a documented outbreak (8) , and all 38 C. coli isolates were included in our susceptibility study.
The 38 C. coli isolates were significantly more resistant to erythromycin, but not to tetracycline or ciprofloxacin, than the 440 C. jejuni subsp. jejuni isolates (Table 1) , similar to data reported previously (1, 2, 9). The 148 C. jejuni subsp. jejuni and 21 C. coli isolates acquired abroad were more resistant to ciprofloxacin, but not to tetracycline or erythromycin, than the 292 C. jejuni subsp. jejuni and 17 C. coli isolates acquired locally ( Fig. 1 and 2 ). In three 4-year time periods (2002 to 2005, 2006 to 2009, and 2010 to 2013), C. jejuni subsp. jejuni isolates acquired abroad were more resistant to ciprofloxacin than were the C. jejuni subsp. jejuni isolates acquired locally (P Ն 0.0002) (data not shown). In each of these 12 years, the number of ciprofloxacin-resistant C. jejuni subsp. jejuni isolates acquired abroad did not increase significantly (chi-square for linear trend, P ϭ 0.052), but the number of ciprofloxacin-resistant C. jejuni subsp. jejuni isolates acquired locally increased significantly (chi-square for linear trend, P ϭ 0.00000) (data not shown). In some studies, travel was associated with increased resistance to ciprofloxacin (9, 10, 11) . With the availability of fluoroquinolones in veterinary and clinical practice, increased resistance of C. jejuni subsp. jejuni and C. coli to ciprofloxacin has been documented along with decreasing efficacy in the treatment of infections with these pathogens (1, 2, 9, 11) . Table 2) . Of the 15 erythromycin-, tetracycline-, and ciprofloxacin-resistant C. jejuni subsp. jejuni/C. coli isolates, 3 and 12 isolates were resistant and susceptible, respectively, to amoxicillin-clavulanic acid (MICs, 64 to 128 and 0.12 to 2 mg/liter, respectively), 1 and 14 isolates were resistant and susceptible, respectively, to gentamicin (MICs, Ͼ256 and 0.12 to 2 mg/liter, respectively), and all 15 isolates were susceptible to imipenem (MICs, 0.015 to 0.25 mg/liter). Two of the 292 C. jejuni subsp. jejuni isolates acquired locally, but none of the 148 C. jejuni subsp. jejuni isolates acquired abroad and none of the 38 C. coli isolates, were erythromycin and ciprofloxacin resistant and tetracycline susceptible.
Erythromycin, tetracycline, and ciprofloxacin susceptibilities were epidemiological markers of C. jejuni subsp. jejuni and C. coli isolates obtained in our hospital (7, 8 ; this study). In the United States, Campylobacter isolates obtained from 2009 to 2011 had resistance rates of 2% to azithromycin, 23% to ciprofloxacin, and 24% to one or the other (11) . Patients who were infected with resistant Campylobacter may have a longer disease duration, increased morbidity, and higher costs (1, 2, 11) . Erythromycin and ciprofloxacin susceptibility should at least be assessed routinely for all C. jejuni subsp. jejuni and C. coli isolates (4). Education on how to prevent Campylobacter infections and surveillance of their antibiotic resistance levels are recommended (1, 2, 11) . New oral drugs are needed for the treatment of enteric Campylobacter infections. 
